申请人:Klein Markus
公开号:US20110190355A1
公开(公告)日:2011-08-04
Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R
3
, R
4
and R
5
have the meanings indicated in Claim
1
, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
式(I)中L、Q、R、X、Y、R3、R4和R5的含义如权利要求书1所示的新型杂环吲唑衍生物是SGK抑制剂,可用于治疗SGK引起的疾病和不适,如糖尿病、肥胖症、代谢综合征(血脂异常)、全身和肺动脉高压、心血管疾病和肾脏疾病,通常用于任何类型的纤维化和炎症过程。